chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had been charting my period cycle and my period following the vaccine was delayed by 7 days (37 day long cycle). I continued to see abnormal periods as well as an increase in acne. My doctor suspected I had developed PCOS. On 8/17/21 I had blood work done which confirmed the diagnosis of PCOS. Additionally, I have been trying to get pregnant since 10/2/2021 with no luck. I have one son (born 9/22/19) and no prior infertility issues. I really feel the vaccine caused the PCOS and infertility issues due to the correlation of the vaccine with the  timing of symptom development.
After the first vaccine, l experienced swollen right lymph node. After the second dose, I see severe flashing of lights and floaters in the right eye. It happened 3 hours after the  2nd vaccine.. l went to see a retina opthlamalogist. He has referred me to a nueroopthalmologist. He thinks the optic nerve is inflamed. This is a reaction to the vaccine. I can barely see out of the right eye and l have 20/20 vision.
Shortly after recieving this vaccine i started to experience really bad headaches, nausea, vomitting, excessive pressure in my head, vision issues. I went to the Dr multiple times for these issues and no one could figure out why i was having so many issues all my labs were normal. This went on for a couple months of them just giving me different meds to try to aleviate the issues i was having. I went in for a routine Eye Exam to get new glasses in December and they said that there was alot of pressure in my eyes and i needed to see a neurologist asap. They ordered a MRI and that is where they noticed the intracranial pressure. I had a CT as well, all showing Psudotumor cerebri. I have had to go through so many meds and had to see the Dr so much. I can barely function in my day to day activities or caring for my three special needs kids.
The patient stated she was feeling somewhat dizzy about 15 minutes after vaccine, but had no other symptoms. We gave her water and checked her blood pressure, which was slightly elevated. Within 5 more minutes she developed chills, and we rechecked blood pressure which had raised from previous check, so we called 911 to have EMS evaluate the patient and potentially transport to the hospital.  She was fully conscious and was able to also speak with the operator who transferred the 911 call to a urgent nurse.  The nurse determined that she was not in immediate harm, but advised the patient to go to the nearest ER  for further testing and evaluation for potential underlying causes. She was transported by the assistant store manager at the approval of the nurse (she did not think ambulance ride was necessary given the symptoms presenting and the patient's answers to her questions).  The pharmacy checked back with the patient last night and she had been discharged from the hospital with no issues - the doctor there told her she was just experiencing a "bad reaction", but no therapies were administered to what we were able to ascertain from the patient. After speaking with the patient again on 04/24 (1 day later) she has recovered from her symptoms fully and states she is tired, but not having any of the symptoms experienced the day before.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, concomitant medications or drug reactions/allergies. On an unspecified date in 2013, the patient was vaccinated with the first dose of GARDASIL for prophylaxis (dose, route of administration, lot number and expiration date were not reported). On 26-FEB-2019, the patient received the second dose of GARDASIL 9 for prophylaxis (dose, route of administration, lot number and expiration date were not reported) (inappropriate schedule of product administration) (interchange of vaccine products). This was longer than the recommended interval. The outcome of inappropriate schedule of product administration and interchange of vaccine products was not reported.
Asymptomatic for approximately 1 hour following immunization administration, TS vomited and reported that she felt her throat was closing. Nurse assessed, delivered .3cc Epinephrine and called 911.
feel tingly & kind of numb; feel tingly & kind of numb; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 24Mar2021 11:00 (Lot number: ER8733) at the age of 55 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Discoid lupus erythematosus" (unspecified if ongoing), notes: Verbatim: Discoid lupus erythematosus (Skin lupus, NOT systemic lupus); "Known allergies: Sulfa" (unspecified if ongoing). Concomitant medication(s) included: SYNTHROID. The following information was reported: PARAESTHESIA (non-serious), HYPOAESTHESIA (non-serious) all with onset 24Mar2021 11:15, outcome "recovering" and all described as "feel tingly & kind of numb". Therapeutic measures were not taken as a result of paraesthesia, hypoaesthesia. Additional information: No other vaccine in four weeks. No COVID prior vaccination. No COVID tested post vaccination.  No follow-up attempts are possible. No further information is expected.
LPN while drawing up a covid vaccine used covid 19 vaccine for 5-11yrs and diluted vaccine with 1.8 ml of normal saline as if drawing up for 12 & up Covid, then administered this vaccine,. Vaccine given was diluted incorrectly and was wrong age group .
Headache over the left eye that caused caused stabbing pain in the left and eye was sensitive to touch like when you have a sinus headache.  Took two ibuprofen and rested.  Took two hous to gio away.
Rapid heart beat. Dizziness, Weakness. Started 1 hour after shot. Lasted 8 hours . Now okay.
This case was reported by a pharmacist and described the occurrence of pain in a 18-year-old male patient who received BEXSERO. In December 2016, the patient received BEXSERO. In December 2016, 1 day after receiving BEXSERO, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved. It was unknown if the reporter considered the pain in arm to be related to BEXSERO. Additional details were reported as follows: This case was not reported previously to anyone. The reporter was a GSK employee who was also a pharmacist. The patient was his son. The patient had a sore arm from the injection. The symptoms ended after about 10 days. The physician's information was unknown. The reporter (GSK employee) had a discussion with another GSK employee, and was reminded that it should be reported, albeit anecdotally. The batch number of the vaccine was unknown.
Pt. received ZOSTAVAX on 11/5/13 and she started feeling sensitive skin on her front and back of trunk. By 11/9/13, pt said she started to have painful rash, and her PCP thinks pt is getting shingles.
Psoriasis flare-up; Vaccination site urticaria; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis flare-up) and VACCINATION SITE URTICARIA (Vaccination site urticaria) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Psoriasis.    Concurrent medical conditions included Psoriasis (Moderate to severe chronic plaque psoriasis).   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced VACCINATION SITE URTICARIA (Vaccination site urticaria). On an unknown date, the patient experienced PSORIASIS (Psoriasis flare-up). In 2021, VACCINATION SITE URTICARIA (Vaccination site urticaria) had resolved. At the time of the report, PSORIASIS (Psoriasis flare-up) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       There was no reported medical history.  Concomitant medications details were not reported.  It was reported that the patient had flare up, bad reaction to covid vaccine broke out in hives in 2021. Patient's physician advised to not take second shot.   Primary reporter does not had the lot number information, because the packaging was discarded for Skyrizi.  The reporter's causality for the events of Vaccination site urticaria and Psoriasis flare-up was reported as Reasonable possibility for Skyrizi.  No treatment information was reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.
Pfizer-BioNTech COVID 19 Vaccine  42 y.o. female had just received her vaccine when she became very lightheaded, was placed on a stretcher and brought to ED further evaluation. Patient has hx of rheumatoid arthritis.  Stated that she has not eaten since earlier this morning, did have some nausea vomiting earlier that is now resolved, feels that it was related to "an adrenaline rush just prior to her vaccination.  Upon arrival to ED she is denying any headache, fever, sweats, chills, cough, shortness of breath, angioedema, chest pain, palpitations, vomiting, edema, claudication, urticarial.  Diagnosed with near syncope.
It presented as a severe headache I went to the ER and I was diagnosed as having had a stroke
A 48-year-old female presents for evaluation treatment of myalgias. She relates it to getting her covid-19 vaccine on 1 7. It is worse at night. Currently is bothering her arms and overnight it was her legs. She has been taking NSAIDs and acetaminophen with no benefit. No fever. No darkening of her urine. Myalgias likely an adverse effect of her vaccine. Normal CBC and BMP.  No evidence of infection, rhabdo. Will prescribe her cyclobenzaprine and she can follow-up as needed.
I have a very interesting patient, date of birth 3/28/1950, who received her first Pneumovax-23 vaccination on 10/18/94 and then had another vaccination on 2/20/04. She is an allergic woman with hives and swelling documented with Augmentin, Bactrim DS, Cephalexin, Cipro, Levaquin, Biaxin, Lorabid, Doxycycline, and Famvir. She had a hysterectomy and BSO in 1999. She is allergic to some foods including pine nuts and sulfites. In addition to seeing an allergist, she takes Zyrtec 10mg a day, Lipitor 10mg a day, and carries an Epi Pen injector. She is using Flonase nasal spray frequently. Despite being followed by an ENT specialist, she has had recurrent sinusitis. On 4/14/04, she was admitted to the hospital with disorientation. She was found to have pneumococcal bacteremia and pneumococcal meningitis with obstructive hydrocephalus. She was admitted to the ICU having received an injection of Cefoxitin in the emergency room. She was treated with IV Penicillin, Vancomycin and Solumedrol. She developed an allergic reaction requiring readmission to the ICU and desensitization to Penicillin starting with very low dosage and then gradually increasing. She had developed significant hearing loss especially in the left ear which occurred about the time of a severe outbreak of herpes simplex on the left side of her face. She had involvement of cranial nerves VI, VII, VIII, XII. She required readmission to the hospital on 5/22/04 when she again appeared disoriented but her cultures were negative. She responded to hydration, antihistamines, glucocorticoids, and Famvir. A skin biopsy documented herpes simplex and eliminated varicella zoster. The reference lab for the hospital using AML found that her Pneumococcal organism was serotype group 19. In the Pneumovax-23 package insert we see that our vaccine included 19F and 19A as two of the 23 capsular antigens. Although this patient did survive she had a well documented and severe illness despite receiving the pneumococcal vaccination ten years before her illness and then again two months before her illness. I am not sure what to do with this information but for those of you who have a special interest in this field, I would want you to be aware of this case. Although the patient has multiple allergies, I am not aware of her having cellular or humoral immunodeficiency. She has had HIV testing which is negative and she has had normal globulin levels. Are there additional studies that we should do on this patient in the future that might be helpful to her or might be helpful to your understanding of how these vaccinations and her infections have worked. Please let me know if you have any advice.
A few days after the first shot I was working outside as golf marshall about 5 pm. Tip of middle finger became painful and numb feeling. Outside temp was about 58 degrees F. Two days later numbness spread to adjoining index and ring fingers. They became very painful and sensitive to touch. Visits to primary care doctor, hand specialist and vascular surgeon is pointing to circulation problem. Finger tip continue to be extremely painful with no relief. Large black areas have formed on two fingers and is spreading to my right hand
Headache, alternating feeling of hot and chills, insomnia, dehydration, and body aches--these symptoms lasted one and half days. Also, arm pain that started at time of injection and lasted for one and half weeks, despite moving arm about and rubbing area.
Went to ER left side of face sagging. They did MRI it showed he had stroke. happened before 4pm that same day as vaccine. Happened between 2-4 pm; Went to ER left side of face sagging. They did MRI it showed he had stroke. happened before 4pm that same day as vaccine. Happened between 2-4 pm; This is a spontaneous report from a contactable consumer (patient). A 78-year-old male patient receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (lot number: EK5730), on 31Dec2020 11:00 AM via unknown route of administration at single dose for COVID-19 immunization. Medical history included high blood pressure, but went up and down and had to readjust. His BP was high and not sure how long it was that way. Concomitant medications included unspecified blood pressure medications. There were no known allergies. Patient went to ER left side of face sagging. They did MRI it showed he had stroke. It Happened before 4pm that same day as vaccine on 31Dec2020 02:00 PM. And it Happened between 2-4 pm. Patient received treatment. Patient had ER test blood, cat scan, MRI. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient did not have been tested for COVID-19. The outcome of the events was recovering. This case was assessed non-serious by reporter. And the events did not result in death, Life threatening, Caused/prolonged hospitalization, Disabling/Incapacitating, Congenital anomaly/birth defect.
Patient contacted the clinic 14 days after receiving her 1st dose of the Moderna vaccine stating the 2nd toe and base of the toe on her right foot was experiencing a sharp pain. She had to walk on the side of her foot.  There was no known injury.  She experienced increased pain when pressure was applied. Xrays showed no injury. About 1 month after symptoms began, the patient began experiencing pain up her leg  to the thigh.
Administration of vaccine adjuvant suspension component (liquid) without active antigen (powder); Administration of vaccine adjuvant suspension component (liquid) without active antigen (powder); This case was reported by a physician via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 28-JUN-2022 and 29- JUN-2022 Reporter's Comments: This case was related to patient 5 of the 5 patients mentioned in case narrative. The GlaxoSmithKline sales representative called GlaxoSmithKline response center the morning of 29th June 2022 to report that the previous day late in the day he was at a medical office and was shown a box of Shingrix. The box had 5 vials of the adjuvant missing.  The sales representative asked what happened to the vials.  The response that was given was that they were administered to 5 patients. No further information was gathered by sales representative such as lot number, patient's initials, patients genders, or route of administration. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up. Additional Supportive Information: The patient was administered vaccine adjuvant suspension component (liquid) without active antigen (powder) component which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. This is 1 of the 5 cases reported by the same reporter. The case US2022AMR100452 was identified as duplicate of US2022101093. The case US2022101093 would be voided, and all the future correspondence would be added in this case US2022AMR100452 which stands as a case of record for this patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR100445:Same reporter US-GLAXOSMITHKLINE-US2022AMR100447:Same reporter US-GLAXOSMITHKLINE-US2022AMR100449:Same reporter US-GLAXOSMITHKLINE-US2022099857:Same reporter US-GLAXOSMITHKLINE-US2022101093:duplicate case (deleted)
Acting a little loopy; Red all over; Trouble breathing; Chills; This spontaneous case was reported by a consumer and describes the occurrence of ABNORMAL BEHAVIOUR (Acting a little loopy), ERYTHEMA (Red all over), DYSPNOEA (Trouble breathing) and CHILLS (Chills) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Mar-2021 at 5:00 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced ABNORMAL BEHAVIOUR (Acting a little loopy), ERYTHEMA (Red all over), DYSPNOEA (Trouble breathing) and CHILLS (Chills). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, ABNORMAL BEHAVIOUR (Acting a little loopy), ERYTHEMA (Red all over), DYSPNOEA (Trouble breathing) and CHILLS (Chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Mar-2021, Oxygen saturation: 97 percent (normal) normal.         Concomitant product use was not provided.  On an unspecified date the patient started to feel better.
Treatment of COVID-19; Treatment of COVID-19; Pfizer -Dose Number: 2; Moderna - Dose Number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 17Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm and on 14Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 63 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 10Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm, on 27Jul2022 as dose 4 (booster), single (Batch/Lot number: unknown), in left arm and on 01Dec2022 as dose 5 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Obesity" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 10Dec2021, outcome "unknown", described as "Pfizer -Dose Number: 2; Moderna - Dose Number: 3"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19, patient was treated with Paxlovid.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was provided regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 13-NOV-2012, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided) at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 26-MAR-2015, the patient was treated by a physician/MD for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. On or about 26-MAR-2015, the patient sought subsequent treatment from the same physician/MD for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and or  despite receiving ZOSTAVAX for the long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the herpes zoster was not recovered. Causality assessment was related. Additional information has been requested.
Heart palpitations, chest pain, chest tightness. Started to go away within two weeks without medication. Visited urgent care, primary care and cardiologist
Tired, Headache, Chills, achy, loss of appetite,  Large red bump at injection site, tender, hot to touch and itchy
pt recvd vax & 5mins later pt fainted, became unresponsive, pale, cold & clammy on extremities & sweating on forehead & upper lips;
Pediarix given at 2mo (9-24-07) in addition to Prevnar and rotavirus and hib: fever 103.4 F at 8 pm on the night of vaccine, pt referred to ER and had sepsis work up which was negative and given ceftriaxone 325mg iv x 2 days until blood cx came back normal.                        Pediarix given at 4mo (12-3-07)in addition to Prevnar and hib: fever 104.5 pt taken to ER via ambulance.  Work up negative again. Contacted DOH vaccines dept 12-28-07 regarding the findings, talked to Dr. Recommended that vaccines be administered separately on different days. DTap given on 2-20-08, pt had low grade fever and developed hives on face and torso, no swelling or respiratory s/s on the night DTap was given. Treated w/ Benadryl. Pt seen by PMD on 2-22-08, residual hives on trunk fading, pt otherwise appeared well. Discussed case w/ DOH, Dr. and Dr., recommended DTap to be given at 15mo since fever and hives not contraindication to vaccination. Also recommended VAERS report.
Pt developed fever ~ 24h after vaccine on 3/14/2022.  c/o L shoulder pain.  On 3/14/22 at 2030 pt temp spiked at 102.6F and tachypnea/tachycardia noted.  CT chest w contrast ordered as well as blood cx.  WBC, lactate, electrolytes wnl; ABG showed resp alkalosis incompletely compensated with mild hypoxia; CXR showed atelectasis vs infiltrate bilaterally without much change to previous CXR.  UA showed possible infection, CTA showed atalectasis/consolidation bilaterally, right segmental pulmonary emobli, bilateral moderate pleural effusions;  Pt received acetaminophen, cefepime, fluconazole,  and treatment dose enoxaparin.